Abstract

BackgroundGiven the costly and time consuming process and high attrition rates in drug discovery and development, drug repositioning or drug repurposing is considered as a viable strategy both to replenish the drying out drug pipelines and to surmount the innovation gap. Although there is a growing recognition that mechanistic relationships from molecular to systems level should be integrated into drug discovery paradigms, relatively few studies have integrated information about heterogeneous networks into computational drug-repositioning candidate discovery platforms.ResultsUsing known disease-gene and drug-target relationships from the KEGG database, we built a weighted disease and drug heterogeneous network. The nodes represent drugs or diseases while the edges represent shared gene, biological process, pathway, phenotype or a combination of these features. We clustered this weighted network to identify modules and then assembled all possible drug-disease pairs (putative drug repositioning candidates) from these modules. We validated our predictions by testing their robustness and evaluated them by their overlap with drug indications that were either reported in published literature or investigated in clinical trials.ConclusionsPrevious computational approaches for drug repositioning focused either on drug-drug and disease-disease similarity approaches whereas we have taken a more holistic approach by considering drug-disease relationships also. Further, we considered not only gene but also other features to build the disease drug networks. Despite the relative simplicity of our approach, based on the robustness analyses and the overlap of some of our predictions with drug indications that are under investigation, we believe our approach could complement the current computational approaches for drug repositioning candidate discovery.

Highlights

  • Given the costly and time consuming process and high attrition rates in drug discovery and development, drug repositioning or drug repurposing is considered as a viable strategy both to replenish the drying out drug pipelines and to surmount the innovation gap

  • Analyses of known indications in disease-drug network Starting with 1976 known indications from Kegg Medicus, we first filtered out diseases and drugs that do not have a known gene association in the Kegg database of disease genes and drug targets

  • We found that of the 1041 known indications only 132 pairs share at least one common gene

Read more

Summary

Introduction

Given the costly and time consuming process and high attrition rates in drug discovery and development, drug repositioning or drug repurposing is considered as a viable strategy both to replenish the drying out drug pipelines and to surmount the innovation gap. Drug repositioning is predominantly dependent on two principles: i) the “promiscuous” nature of the drug and ii) targets relevant to a specific disease or pathway may be critical for other diseases or pathways [3,4] The latter may be represented as a shared gene or feature (biological process, pathway, or phenotype) between a disease-disease, drug-drug, or a disease-drug. Based on this principle, some computational approaches (see recent review [5]) have been developed and applied to identify drug repositioning candidates ranging from mapping gene expression profiles with drug response profiles [6,7,8,9,10,11,12], to side-effect based similarities [13,14,15]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call